Clinical Trial Update: EBV-TCR-T（YT-E001）for Patients With EBV-positive Recurrent or Metastatic NPC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for EBV-TCR-T (YT-E001) in EBV-positive recurrent or metastatic nasopharyngeal carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• EBV-TCR-T (YT-E001)

Snippet

Sponsor: Fujian Cancer Hospital | Conditions: Nasopharyngeal Carcinoma | Phase 2 | Status: UNKNOWN